BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23668484)

  • 21. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.
    Sun D; Wang Z; Caille S; DeGraffenreid M; Gonzalez-Lopez de Turiso F; Hungate R; Jaen JC; Jiang B; Julian LD; Kelly R; McMinn DL; Kaizerman J; Rew Y; Sudom A; Tu H; Ursu S; Walker N; Willcockson M; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2011 Jan; 21(1):405-10. PubMed ID: 21093258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
    Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
    J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
    Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
    J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
    J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
    Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
    Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors.
    Cole AG; Bohnstedt AC; Paradkar V; Kingsbury C; Quintero JG; Park H; Lu Y; You M; Neagu I; Diller DJ; Letourneau JJ; Shao Y; James RA; Riviello CM; Ho KK; Lin TH; Wang B; Appell KC; Sills M; Quadros E; Kimble EF; Ohlmeyer MH; Webb ML
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6788-92. PubMed ID: 19836234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
    Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
    J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis.
    Bright JJ; Du C; Sriram S
    J Immunol; 1999 May; 162(10):6255-62. PubMed ID: 10229872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
    Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
    J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
    Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
    J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.